Objectives. To evaluate whether there is a correlation between the differences in joint uptake of 2-[18F]-fluoro-2-deoxy-D-glucose ( 18 F-FDG) and the improvement of clinical findings in RA patients undergoing anti-TNF therapies.
Introduction
The main pathological manifestations of RA include synovitis, pannus formation and bone erosion. These pathological changes are usually assessed by plain X-ray, US, CT and contrast-enhanced, fat-suppressed MRI. PET with 2-[
18 F]-fluoro-2-deoxy-D-glucose ( 18 F-FDG) can be used to evaluate the metabolic activity of synovitis and measure the disease activity in RA patients by whole-body imaging [14] . Imaging studies using 18 F-FDG-PET have been performed to assess the metabolic activity of synovitis in patients with RA and to evaluate the disease activity of RA [511] . Several reports have indicated that there was a significant correlation between the visual assessment of FDG uptake, i.e. the visual uptake score and clinical evaluation of disease activity [6, 9] . Furthermore, PET findings have been correlated with MRI and US assessments of the pannus in patients with RA [35] as well as with the classical serum parameter of inflammation, CRP and the synovium-derived parameter, serum MMP-3 [3] .
Recent advances in medical biology and pharmaceutical engineering have provided new drugs, such as TNF inhibitors, anti-IL-6 receptor antibodies and anti-CD20 antibodies for the treatment of RA patients [12] . Clinical application of novel therapies for RA has stimulated increased interest in the radiological assessment of the disease activity. Since an incomplete response leads patients who have been undergoing these biologic therapies to discontinue the treatment, which has high costs and possible side effects, monitoring of the specific biologic response to the therapies might be helpful for the clinicians to determine suitable treatments. Therefore, the development of molecular imaging methods would be beneficial, especially in RA patients.
One of the merits of PET is that it enables quantitative measurement of metabolic activity.
18 F-FDG-PET studies have been proposed to assess the metabolic activity measured quantitatively by the standardized uptake value (SUV) of articular lesions in patients with RA. In the present study we evaluated whether the FDG uptake of the affected joints represented by the SUV correlated with the clinical assessment of patients with RA. In addition, we evaluated if there was a correlation between the differences in the SUV and the improvement of the clinical findings in RA patients receiving anti-TNF therapies.
Materials and methods

Patients and methods
The institutional review board of the hospital approved the study, and informed consent was obtained from each patient. The average disease duration of these patients was 13.2 (149) years. The average dose of MTX for the 22 patients was 5.1 mg/week, and the average dose of prednisolone (PSL) was 2.9 mg/day (Table 1) . After the baseline assessment using whole-body 18 F-FDG-PET/CT (FDG-PET/CT), they underwent the biologic therapies. The FDG-PET and clinical assessments were also performed 6 months after the initiation of the therapies. Clinical assessments included ESR, serum concentrations of CRP, MMP-3 and RF. The activity of inflammation was evaluated using both the DAS28 and the DAS28-CRP. The DAS28 was calculated based on the results of the 28 tender joint count (TJC), 28 swollen joint count (SJC) and ESR. The DAS28-CRP was calculated using the TJC, SJC and CRP. For the calculation of the DAS28 and DAS28-CRP scores, the following formulas [14] were used:
DAS28 ¼½0:56 Ã sqrtðTJC28Þþ0:28 Ã sqrtðSJC28Þ þ 0:70 Ã LnðESRÞ Ã 1:08 þ 0:16, DAS28-CRP ¼½0:56 Ã sqrtðTJC28Þþ0:28 Ã sqrtðSJC28Þ þ 0:36 Ã lnðCRP þ 1Þ Ã 1:10 þ 1:15
Clinical improvement was assessed by the changes in the DAS28 after the therapy according to the European League Against Rheumatism (EULAR) response criteria [15] .
PET images
Whole-body PET was performed following i.v. injection of 18 F-FDG (5 MBq/kg) after the patient had fasted for >6 h.
Data acquisition was done in 3D mode 60 min after the injection using a PET-CT scanner (Biograph 16; Siemens Medical Solutions Inc., Munich, Germany). Patients were scanned from the head to the toe in the arms-down position. Attenuation correction of the PET images was performed using CT, followed by reconstruction using an ordered subsets expectation-maximization algorithm into 128 Â 128 matrices. PET images were interpreted by experienced nuclear physicians, and increased FDG uptake in bilateral shoulder, elbow, wrist, hip, knee and ankle joints was recorded. We selected these joints for the evaluation of the FDG uptake because these joints were suitable for the clinical assessment of RA patients. These large joints needed no additional or separate scanning or the use of auxiliary devices, such as those needed for the scanning of finger lesions, which reduces the burden for patients. In addition, the easy-to-use area settings lead to decreased intra-and interobserver differences for nuclear physicians.
Data analysis
For the semiquantitative analysis, functional images of the SUV were produced using attenuation-corrected transaxial images, the injected doses of FDG, the patient's body weight and the cross-calibration factor between PET and dose calibrator. The SUV was defined as follows:
SUV ¼radioactive concentration in the region of interest ðROIÞ ðMBq=gÞ=injected dose ðMBqÞ= patient 0 s body weight: ROIs were manually drawn at each joint on the SUV images. The ROI analysis was conducted by a nuclear physician with the aid of corresponding CT scans. The maximal SUV in the ROI was used as a representative value for the assessment of the FDG uptake. For assessment of therapeutic response, the clinical parameters DAS28, DAS28-CRP, ESR, CRP, MMP-3 and RF were obtained at the same time as the PET study. The therapeutic response was evaluated by the changes in the mean value of the maximal SUV of the affected joints (mean SUV) and the DAS28. We used all 12 joints evaluated by FDG-PET or 8 (bilateral shoulder, elbow, wrist and knee) joints which were represented in the DAS28 for the calculation of the average SUV max . The ÁSUV, ÁDAS28 and ÁDAS28-CRP (ÁDAS28-CRP) were defined as follows:
In the above formula, the meanSUV pre , meanSUV 6m , DAS28 pre , DAS28 post , DAS28-CRP pre and DAS28-CRP 6m represent the mean SUV at baseline, the mean SUV after treatment, the DAS28 at baseline, the DAS28 after treatment, the DAS28-CRP at baseline and the DAS28-CRP after treatment for each patient. In the following result section, Á indicates the difference in the values before and after treatment.
Statistical analysis
The treatment responses were evaluated on both a patient and a joint basis. Wilcoxon's signed rank sum tests were used to assess the differences in the evaluations of the treatment. Spearman's rank correlation test and the partial correlation analyses were applied to test for correlations of the different parameters recorded in this study. The IBM SPSS Statistics 19 software program (International Business Machines Corp., New York, NY, USA) was used for the analysis. P < 0.05 was considered to be statistically significant. For multiple correlations we used Bonferroni's correction [16] , and the significance of correlation coefficients was calculated.
Results
PET-CT images of a typical case, both prior to therapy and at the follow-up examination, are provided in Fig. 1 Table 2) .
We evaluated the responses of the RA patients to these therapies based on the FDG-PET/CT results and the clinical parameters. The values of all disease parameters were significantly decreased after biologic treatment compared with baseline ( Table 2) .
We next performed the joint-based analyses for the 12 or 8 joints of each of the 22 RA patients. We evaluated the changes in the existence of the tender joints and swollen joints. Additionally, the SUV of the affected joints before and after the biologic treatments were assessed for each joint in each patient. The tenderness of the joints in the right shoulder, left wrist and right knee were significantly decreased after the biologic treatment. The swollen joints of bilateral elbows and bilateral wrists were also found to be decreased after treatment when evaluated on an individual joint basis. The SUV of the left shoulder, right elbow, bilateral wrists, bilateral knees, right hip and right ankle were decreased compared with the SUV at baseline in each patient (Table 3) .
At baseline the SUV (12 joints) was correlated with the TJC (r = 0.578, P = 0.005). The SUV (8 joints) was correlated with the DAS28 (r = 0.588, P = 0.004), DAS28-CRP (r = 0.712, P = 0.003) and TJC (r = 0.621, P = 0.002) ( Table 4) .
Six months after treatment the SUV (12 joints) was correlated with the DAS28 (r = 0.577, P = 0.005), DAS28-CRP (r = 0.568, P = 0.006) and ESR (r = 0.623, P = 0.002). The SUV (8 joints) was correlated with the DAS28 (r = 0.602, P = 0.003), DAS28-CRP (r = 0.597, P = 0.003), ESR (r = 0.580, P = 0.005) and SJC (r = 0.567, P = 0.006) ( Table 4) .
The ÁSUV (12 joints), the difference in the SUV max of the 12 affected joints before and after treatment, was significantly correlated with the ÁDAS28 (r = 0.609, P = 0.003), ÁDAS28-CRP (r = 0.656, P = 0.001) and ÁTJC (r = 0.609, P = 0.003). There was no correlation between the ÁSUV (12 joints) and ÁMMP-3 after Bonferroni's correction (r = 0.499, P = 0.018). The ÁESR (r = 0.412, P = 0.057), ÁCRP (r = 0.340, P = 0.121), ÁRF (r = 0.149, P = 0.507) and ÁSJC (r = 0.222, P = 0.320) did not correlate with the ÁSUV (12 joints) ( Table 4) .
There were also significant correlations between the ÁSUV (8 joints), the difference in the SUV max of the bilateral shoulder, elbow, wrist and knee joints before and after treatment and the ÁDAS28 (r = 0.642, P = 0.001), ÁDAS28-CRP (r = 0.712, P < 0.001) and ÁTJC (r = 0.608, P = 0.003), respectively (Table 4) .
We also used partial correlation coefficients to examine whether the ÁCRP or ÁESR had any effect on the correlations between the ÁSUV and ÁDAS28 or ÁDAS28-CRP. Data are given as mean (S.D.) (range). The average of each parameter was calculated before and after treatment. All disease parameters were significantly decreased after biologic treatment. *P < 0.05, **P < 0.005 and ***P < 0.001, indicating significant differences compared with the parameters at baseline.
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When ÁCRP was the control variable, there were partial correlations between the ÁSUV (12/8 joints) and the ÁDAS28 (Table 5 ). There were also partial correlations between the ÁSUV (12/8 joints) and the ÁDAS28-CRP when ÁESR was the control variable (Table 5 ).
Discussion
The results of this study indicated that the total SUV max closely correlated with the disease activity of RA. Kubota et al. [9] demonstrated that the visual FDG uptake score Before treatment, the SUV (12 joints) was correlated with the TJC. The SUV (8 joints) was correlated with the DAS28, DAS28-CRP and TJC. Six months after treatment the SUV (12 joints) was correlated with the DAS28, DAS28-CRP and ESR. The SUV (8 joints) was correlated with the DAS28, DAS28-CRP, ESR and SJC. The ÁSUV (12/8 joints), the difference in the SUV max of the affected 12 or 8 (bilateral shoulder, elbow, wrist and knee) joints before and after treatment, was significantly correlated with the ÁDAS28, ÁDAS28-CRP and ÁTJC. There was no correlation between the ÁSUV (12/8 joints) and ÁMMP-3.
a Indicates significant correlation after Bonferroni's correction. The TJC of the right shoulder, left wrist and right knee were significantly decreased after biologic treatment when evaluated on a joint basis in each patient. The SJC of bilateral elbows and bilateral wrists was decreased after treatment when evaluated on a joint basis in each patient. The SUV of the left shoulder, right elbow, bilateral wrists, bilateral knees, right hip and right ankle was decreased compared with the SUV at baseline in each patient. *P < 0.05 and **P < 0.005, indicating significant differences compared with the parameters at baseline (Wilcoxon's signed rank sum test).
might be useful for evaluating arthritis in large joints. They studied 18 RA patients using a scoring system modified from the Goerres's scoring system [6] . The total FDG score was found to be significantly correlated with the CRP level. Although rheumatologists usually examine patients by calculating scores such as the DAS28 or DAS28-CRP, which include subjective items, to assess the treatment response, whole-body imaging with FDG-PET seems to provide an alternative and objective evaluation method, or at the very least, an additional tool to provide assistance with the evaluation. With regard to this point, the SUVs might be able to provide a better description for the joint FDG uptake than visual uptake scores. Hence, in the present study, we evaluated the FDG uptake using SUVs, not visual uptake scores.
It has so far been reported that the SUVs obtained from 18 F-FDG-PET assessment of rheumatoid synovitis were correlated with MRI findings, with the SUVs being closely correlated with the volume of the enhancing pannus [35] . In addition, Beckers et al. [3] examined 356 joints of 21 patients and showed that 18 F-FDG-PET imaging could assess the metabolic activity of synovitis and measure the disease activity of the RA. The SUVs were highly correlated with the synovial thickness measured by US. The authors of that study also assessed 16 knees in 16 patients with active RA with PET, MRI and US at baseline and 4 weeks after initiation of anti-TNF-a treatment. The SUVs were significantly correlated with all MRI parameters, synovial thickness and serum CRP and MMP-3 levels at baseline. The changes in the SUVs after 4 weeks of treatment also correlated with the changes in the MRI parameters and in the serum CRP and MMP-3 levels in their study.
While SUVs correlated with the clinical status of the patients, the SUVs noted above were based on monoarthric assessments, and none of the previous reports simultaneously evaluated multiple joints throughout the body to assess the clinical condition or treatment responses of the patients. Therefore, in this study, to provide a semiquantitative analysis and to focus on the potential utility of FDG-PET in clinical practice, we conducted whole-body FDG-PET/CT and used the SUV max to determine the FDG uptake.
The difference in the mean SUV max between studies before and after anti-TNF therapies might reflect the changes in the disease activity resulting from the medication, because these values were significantly correlated with the differences in the DAS28 and DAS28-CRP in this study. Goerres et al. [6] assessed seven RA patients prior to and 12 weeks after IFX treatment using FDG-PET imaging-based total joint scores and concluded that visual assessment of the FDG uptake showed a significant correlation with the clinical evaluation of disease activity performed by the rheumatologist in patients undergoing anti-inflammatory treatment.
In a previous study, Kubota et al. [9] indicated that the total SUV max and the CRP levels were weakly, but not significantly, correlated. In our study, the CRP levels at baseline and after treatment were not significantly correlated with the total SUV max , and the ÁCRP was not significantly correlated with the ÁSUV. On the other hand, Beckers et al. [10] demonstrated in 16 rheumatoid knees that the SUVs were significantly correlated with serum CRP levels at baseline and that the changes in the SUVs after TNF therapy were also correlated with changes in serum CRP levels. The reason why the CRP did not correlate with the total SUV may be that the CRP in itself cannot reflect the whole-body disease activity of RA patients. Since the CRP tends to mirror the swelling of the larger joints of the human body, the FDG uptake of the knee, one of the largest joints, might correlate best with the serum CRP levels. Further evaluation is needed to assess the relationship between the CRP and the SUVs.
Another question to be answered was whether FDG-PET detects subclinical arthritis better than MRI. MRI is sensitive for depicting morphological changes by estimating the pannus volume or synovial thickness in the early stage of the disease. An early and accurate diagnosis is the key to optimal treatment in patients with RA. However, these studies are limited to morphologybased information. Furthermore, high-resolution, contrast-enhanced MRI is limited to circumscribed areas of the body. Beckers et al. [3] demonstrated that PET-positive knees exhibited significantly higher SUVs, higher MRI parameters and greater synovial thicknesses compared with PET-negative knees, whereas the serum CRP and MMP-3 levels were not significantly different. Additionally, Kubota et al. [9] suggested that FDG-PET could identify joints with active RA inflammation more sensitively than monitoring the clinical signs/symptoms of RA. Therefore, FDG-PET might be more suitable for the detection of subclinical arthritis than other modalities. We hypothesized that FDG-PET would be able to detect a clinical response in both patients with RA and in their individual joints. In this study, we compared the changes in the SUVs with the clinical response of the patients and the tender/swollen joints to biologic treatments 6 months after initiating the treatment. As a result, the SUV and patients' disease status were found to be significantly decreased compared with the baseline. These effects were due to the 6 months of treatment. Biologic therapies usually exert a rapid effect against RA, and can sufficiently reduce disease activity 6 months after the initiation of treatment. Although therapeutic effects on the left shoulder, left knee, right hip and right ankle joints were not clinically detectable, the SUVs of the joints were still significantly decreased compared with the baseline in each patient. Our data indicated that the FDG-PET might be sensitive to the changes of tender/swollen joints to detect the responses of the biologic treatment. Further cross-sectional and longitudinal studies are needed before 18 F-FDG-PET can be considered one of the qualitative clinical evaluation technologies for the assessment of therapeutic effects in RA patients.
In the present study, the SUV was closely correlated with the disease activity of RA; however, the precise pathological condition of RA reflected by the 18 F-FDG-PET has not been understood. It has been reported that pro-inflammatory cytokines such as TNF-a and hypoxia might contribute to the 18 F-FDG uptake by cells involved in pannus formation in RA [17] ; therefore, the 18 F-FDG accumulation in RA patients may reflect the proliferation of the pannus and inflammatory activity. The disease activity and FDG uptake were significantly correlated in the present study, and these findings were consistent with a previous study [6, 9] . In the clinical examination of RA patients, because metabolic changes are likely to precede morphological changes, that is to say, the activated synovitis directly lead to the future joint destruction,
18
F-FDG-PET accumulation may provide important biologic information for the rheumatologist to ensure strict disease control in RA patients.
The limitations of this study were the small number of patients and the number of assessed joints. The FDG-PET/CT instruments were only introduced in limited facilities, which restricted the number of examinations that could be performed. Further investigation is needed to assess the inflammation of RA joints. With regard to the radiation given to the RA patients, we made a dose reduction by the CT-based attenuation correction method, which reduced the radiation dose levels because the tube current was lower than that used for diagnostic CT.
In conclusion, the FDG uptake observed in the inflamed RA joints can reflect the disease activity. FDG-PET might play an important role in the evaluation of the biologic treatment for RA.
Rheumatology key messages
.
18
F-FDG-PET can image the extent of inflammation in patients with RA. . The differences in SUVs may reflect the therapeutic effects of RA treatments. . FDG-PET can be used to evaluate the response of RA patients to biologic treatment.
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